Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
June 27, 2023
- Ryukaikon Calls for Correcting Excessive Yakkasa by Revising Distribution Guidelines
June 27, 2023
- Ryukaikon to Discuss Drug Categories to Be Separated from Bundled Trades
June 27, 2023
- Japan Reports World’s 1st Death from Oz Virus
June 26, 2023
- PMDA Reviewing Safety Risks for 10 Statin Drugs, Tirzepatide
June 26, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- Avigan, 3 Other Drugs Get Orphan Status in Japan
June 23, 2023
- Chuikyo Kicks Off Debates toward FY2024 Drug Price Reform
June 22, 2023
- Chuikyo OKs Drug Price Survey Plan for FY2024 Revision
June 22, 2023
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- MHLW Panel Discusses 6 Risks to Drug Supplies; Need for Industry Consolidation Raised
June 21, 2023
- MHLW to Set Up Separate Forums Focused on Generics and Drug Lags to Execute Expert Panel Proposals
June 21, 2023
- Ryukaikon to Meet June 26 to Discuss Expert Panel Proposals
June 21, 2023
- MHLW Study Group to Develop Company Indicators for Generic Supply Systems in FY2023
June 20, 2023
- MHLW Study Group Proposes Flexibility in Launch Premium Criteria, Broader Comparators
June 20, 2023
- MHLW Starts Clinical Study on Mpox Vaccine for People with High Infection Risks
June 19, 2023
- PMDA to Establish Asia, US Hubs to Spur Innovative Drug Development
June 19, 2023
- Japan OKs Honebuto Budget Policy Blueprint, Vows Debates on Longer-Term Drug Costs
June 19, 2023
- Democratic Party For the People Calls for Drug Pricing Overhaul
June 16, 2023
- First Generics for 11 APIs to Enter NHI Price List, Azilva Faces Most Contenders
June 15, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…